Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study
It has been suggested that a partial dose reduction of S-1 as adjuvant chemotherapy for PDAC does not significantly impact prognosis.
Authors
- Masato Yamadera (ORCID: https://orcid.org/0000-0002-0672-4259)
- Naoto Yonamine
- Takahiro Einama
- Eiji Shinto
- Makoto Nishikawa (ORCID: https://orcid.org/0000-0002-6675-8952)
- Akifumi Kimura (ORCID: https://orcid.org/0000-0003-2445-2557)
- Hideki Ueno (ORCID: https://orcid.org/0000-0001-7747-0738)
- A. Ide
- Yoji Kishi (ORCID: https://orcid.org/0000-0001-8885-1210)
- Yoshifumi Beck (ORCID: https://orcid.org/0000-0001-6894-7805)
- Takazumi Tsunenari (ORCID: https://orcid.org/0000-0002-9852-6929)
- Yoichi Miyata (ORCID: https://orcid.org/0000-0002-5201-4477)
- Mikiya Takao (ORCID: https://orcid.org/0009-0003-2929-2086)
- Kazuki Kobayashi (ORCID: https://orcid.org/0000-0002-9365-9490)
Institutions
- National Center for Global Health and Medicine (JP)
- Self-Defense Forces Central Hospital (JP)
- National Defense Medical College (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1007/s10147-025-02742-0
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Defense Medical College